Dr. Ajit Singh, an Indian American veteran of the diagnostics industry has been appointed CEO of Harbinger Health, a biotechnology company pioneering the detection of early cancer, and CEO-Partner of Flagship Pioneering, a bioplatform innovation company.
Singh who succeeds Stephen Hahn, will also continue as a Harbinger board member, a role he has held since 2024, according to a press release.
Singh brings extensive expertise in the development and commercialization of advanced diagnostics, most notably from his tenure at Siemens and his leadership at several companies that successfully launched in vitro diagnostics products, primarily in the oncology sector.
His appointment comes at a vital time for Harbinger as the company focuses on development of multiple products aimed at transforming early cancer detection based on clear validation of the company’s platform, the release stated.
“Ajit’s profound understanding of the diagnostics industry and demonstrated track record of success leading growth companies will be invaluable to building Harbinger to its full potential and, in his capacity as CEO-Partner, to enhancing our broader Flagship ecosystem,” said Doug Cole, M.D., Co-founder and Board Chair, Harbinger and General Partner at Flagship Pioneering.
READ: Amid layoffs, Oracle Health unveils next-gen AI-powered EHR (August 14, 2025)
Singh shared, “Early cancer detection remains one of the most critical, yet unsolved, challenges in oncology. Harbinger Health has a unique opportunity to solve this through its deep insights into the biology of cancer’s origins paired with advanced sequencing technologies and the transformative power of AI. I am excited to lead the team as we strive to make earlier cancer detection a reality, improving outcomes for millions.”
Harbinger is developing blood-based tests that use specific proprietary methylation patterns of cell-free ctDNA in blood to detect the presence of cancer.
It has developed a platform that combines unique insights into the biology of cancer’s origin with artificial intelligence and analytical and methodological innovations to create novel diagnostic and screening products in multiple clinical settings and cancer indications.
The company recently presented data demonstrating the potential of its assays to detect multiple high-incidence, high-mortality cancers related to obesity and multiple platform innovations and analytical methodologies to enhance cancer signal detection and improve performance.
Ajit Singh was most recently at Artiman Ventures where he focused on early-stage technology and life science investments and represented the firm on the boards of Aditazz, CORE Diagnostics and OncoStem Diagnostics.
READ: Best health insurance for Indian tourists in America: Plans and costs explained (August 11, 2025)
Singh is also an Adjunct Professor in the School of Medicine at Stanford University and serves on the Board of Trustees of the American Association for Cancer Research (AACR).
Prior to joining Artiman, Singh was the President and CEO of BioImagene (acquired by Roche), a Digital Pathology company. Before BioImagene, he spent nearly twenty years at Siemens in various roles, most recently as the Chief Executive Officer of the Digital Radiology and Medical Informatics business of Siemens Healthcare.
His previous roles included President and CEO of the Oncology Care Systems Group, Group Vice President of Siemens e-Health, and Vice President of Siemens Health Services. From 1989 to 1995, he was at Siemens Corporate Research working on Artificial Intelligence, Robotics, Computer Vision, and Image Analysis. During this time, he concurrently served on the faculty at Princeton University.
Dr. Singh has a Ph.D. in Computer Science from Columbia University, a master’s degree in Computer Engineering from Syracuse University, and a bachelor’s degree in Electrical Engineering from Banaras Hindu University, India. He has published two books and numerous refereed articles and holds five patents.